Due to a friendly regulatory environment, as well as the upsurge in market cap, it was a good year for the biotech and pharmaceutical industry in 2013. Five of the companies saw their market cap more than double: BioMarin Pharmaceutical, Isis Pharmaceuticals, Onyx Pharmaceuticals, Vertex Pharmaceuticals, and especially Gilead Sciences, which, according to GEN “nearly tripled after spending recent months integrating Pharmasset and growing its strong HIV portfolio with approvals last year for the combination drug Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), as well as and the first drug indicated for preventing the AIDS virus, the combo treatment Truvada (emtricitabine and tenofovir disoproxil fumarate).”
The aforementioned companies saw a strong number of drugs through trials and post to market. The list below, are the top the biotech had to offer this last year. Is your company included?
The top 25 Biotech companies are:
#25- Isis Pharmaceuticals
#24- Ipsen Group
#23- United Therapuetics
#22- Cubist Pharmaceuticals
#21- Ariad Pharmaceuticals
#20- Alkermes
#19- Seattle Genetics
#18- Dr Reddy’s Laboratories
#17- Onyx Pharmaceuticals
#16- Actelion
#15- Elan
#14- BioMarin Pharmaceuticals
#13- UCB
#12- Vertex Pharmaceuticals
#11- Shire
#10- Alexion
#9- Regeneron
#8- CSL
#7- Merck KGaA
#6- Teva Pharmaceuticals
#5- Biogen Idec
#4- Celgene
#3- Gilead Sciences
#2- Amgen
#1- Novo Nordisk
